All News
FDA Approves Simponi Aria for Psoriatic Arthritis and Ankylosing Spondylitis
Janssen Biotech, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).
Read Article
The RheumNow Week in Review - 20 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.
Read Article
Hepatitis A Outbreak in San Diego
On Sept. 1, 2017, the San Diego County declared a local public health emergency due to the ongoing hepatitis A outbreak in the county.
Read Article
Tofacitinib Scores in TNF inhibitor Resistant Psoriatic Arthritis
Mease et al has reported in the NEJM the results of a phase 3 trial showing tofacitinib (Tofa) to be significantly more effective than placebo in active psoriatic arthritis (PsA) patients who previously failed to respond to tumor necrosis factor inhibitor (TNFi) therapies.
Read Article
Rheumatologists are Slow to Change DMARDs
The paradigm of rheumatoid arthritis (RA) therapy mandates early diagnosis and aggressive treatment. Yet a recent cohort study has shown that RA patients with moderate to high disease activity (MHDAS) were met with infrequent DMARD adjustments; with median time to DMARD adjustment being 5 months and median time to low disease activity (LDAS) was roughly 10 months.
Read Article
Gout Increases Risk of Stroke Moreso than MI
Gout coassociates with many of the disorders within the metabolic syndrome - diabetes, hypertension, hyperlipidemia and obesity. Not surprisingly, gout is a risk factor for cardiovascular disease, but the risk magnitude for myocardial infarction (MI), and stroke are unclear.
Read Article
Stelara FDA Approved for Use in Adolescent Psoriasis
Johnson & Johnson has announced that they have received an expanded FDA approval for the use of ustekinumab (Stelara) in treating adolescent patients, aged 12 and over, with moderate to severe plaque psoriais.
Read Article
High Drug Discontinuations and Nonadherence in Fibromyalgia
Compliance and adherence was shown to be quite poor in fibromyalgia (FM) patients, with high rates of drug discontinuation and greater than 60% demonstrated low adherence.
Read Article
Spinal X-ray Inhibition in Ankylosing Spondylitis Best Achieved by Control of Activity
Although tumour necrosis factor inhibitors (TNFi) are highly effective (on clinical grounds) in ankylosing spondylitis (AS), proof that they may alter the course of spinal radiographic progression has been scant.
Read Article
13 October 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!
Read Article
The Big Need - NPs and PAs
Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline. These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S.
Read Article
Novel Gel Drug Delivery Developed for Rheumatoid Arthritis
Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis.
Read Article
Arthritis Burden over $303 Billion Annually in U.S.
Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.
Read Article
BSR Guidelines on Lupus Management
In the UK, NICE has accredited the British Society of Rheumatology (BSR) to develop a guidance document on the management of systemic lupus erythematosus in adults. The last published guidelines for lupus were published in 2008 by EULAR and in 2012 by the ACR.
Read Article
Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee
Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.
Read Article
2016 EULAR Guidelines on RA Management
The management of rheumatoid arthritis (RA) has evolved significantly with time. Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.
Read Article
The RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.
Read Article
Patterns of Biologic Use During Autoimmune Pregnancy
While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.
Read Article
IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases
A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).
Read Article
Alcohol Related Deaths Increased in Psoriasis
JAMA Dermatology has published a report showing psoriasis carries a 60% greater risk alcohol-related death compared with those without psoriasis. (Citation source: https://buff.ly/2galDwr)
Read Article